Cannabinoid compositions, and uses thereof in treatment of neurodegenerative diseases or disorders and cancers

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
A cannabinoid composition of CBD, CBG, and THC targets Tau protein to address the lack of effective treatments for neurodegenerative diseases and cancer, offering a novel therapeutic solution.

HK40134815APending Publication Date: 2026-07-10BIOPHARMACEUTICAL RESEARCH COMPANY

Patent Information

Authority / Receiving Office: HK · HK
Patent Type: Applications
Current Assignee / Owner: BIOPHARMACEUTICAL RESEARCH COMPANY
Filing Date: 2026-05-25
Publication Date: 2026-07-10

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases and cancer lack effective therapeutic agents targeting the microtubule-associated protein Tau.

Method used

A cannabinoid composition comprising cannabidiol (CBD), cannabinol (CBG), and tetrahydrocannabinol (THC) is formulated to target and treat neurodegenerative diseases and cancer, utilizing these components in specific proportions for therapeutic efficacy.

Benefits of technology

The cannabinoid composition effectively targets and treats neurodegenerative diseases and cancer by modulating the microtubule-associated protein Tau, providing a novel therapeutic approach.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

Cannabinoid compositions formulated for use in the treatment of neurodegenerative diseases and conditions, and cancer are disclosed. The treatment methods herein may be targeting the microtubule associated protein Tau. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of neurodegenerative diseases and conditions, and cancer.

Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention discloses cannabinoid compositions for the treatment of neurodegenerative diseases and conditions, as well as cancer. The therapeutic methods described herein can target the microtubule-associated protein Tau. The composition comprises cannabidiol (CBD), cannabinol (CBG), and tetrahydrocannabinol (THC) as its main components, which can be isolated, purified, or extracted from cultivated varieties and blended together. The composition comprises a certain proportion of CBD, CBG, and THC and is formulated for the treatment of neurodegenerative diseases and conditions, as well as cancer.

Claims

776772000140 CLAIMS What is claimed is:

1. A cannabinoid composition, comprising: cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition, wherein the CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars.

2. The composition of claim 1, wherein the CBD, CBG and / or THC are provided as botanical drug substances (BDS).

3. The composition of claim 2, further comprising other cannabinoid and / or non- cannabinoid components that are present from the BDS.

4. The composition of claim 2, further comprising terpenes that are present from the BDS.

5. The composition of any one of claims 2 to 4, further comprising flavonoids that are present from the BDS.

6. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of cannabis extracts.

7. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of extracts from 2-4 cannabis cultivars.

8. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of extracts from genetically identical clones of 3 different cannabis cultivars.

9. The composition of claim 8, wherein the 3 different cannabis cultivars are a high CBD cultivar, a high CBG cultivar and a high THC cultivar.

10. The composition of any one of claims 7 to 9, wherein cannabis cultivars are Cannabis sativa cultivars. sf-5716649776772000140 11. The composition of any one of claims 6 to 10, further comprising other cannabinoid and / or non-cannabinoid components that are present from the extracts.

12. The composition of any one of claims 6 to 10, further comprising terpenes that are present from the extracts.

13. The composition of any one of claims 6 to 11, further comprising flavonoids that are present from the extracts.

14. The composition of any one of claims 2 to 13, further comprising additional CBD, CBG and / or THC provided in purified form.

15. The composition of any one of claims 2 to 13, further comprising additional CBD, CBG and / or THC isolates.

16. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of purified CBD, CBG and THC cannabis extracts.

17. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of CBD, CBG and THC isolates.

18. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of BDS and CBD, CBG and / or THC isolates.

19. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of BDS, and purified CBD, CBG and / or THC cannabis extracts.

20. The composition of claim 1, wherein the CBD, CBG and THC are provided as a combination of BDS, and CBD, CBG and / or THC isolates.

21. The composition of claim 1, wherein the CBD, CBG and THC are provided as BDS in combination with refined or synthetic CBD, CBG and / or THC.

22. The composition of claim 1, wherein the CBD, CBG and THC are a combination of highly purified CBD, highly purified CBG and highly purified THC, wherein each of which are sf-5716649776772000140 extracted from a cannabis plant and purified to the extent that other cannabinoids and a majority of non-cannabinoid components that are co-extracted with the cannabinoids have been removed.

23. The composition of claim 22, wherein the highly purified CBD is greater than or equal to 90% (w / w) pure; the highly purified CBG is greater than or equal to 90% (w / w) pure; and the highly purified THC is greater than or equal to 90% (w / w) pure.

24. The composition of claim 1, wherein the CBD, CBG and THC are all naturally derived.

25. The composition of claim 1, wherein at least a portion of the CBD, CBG and / or THC is naturally derived, and the other portion is synthetic and / or biosynthetic.

26. The composition of any one of the preceding claims, wherein the THC is present primarily in the form of (–)-delta-9-trans-tetrahydrocannabinol (Δ9-THC).

27. The composition of any one of the preceding claims, wherein the CBD, CBG and THC are collectively greater than 50% by weight of the cannabinoids present in the composition.

28. The composition of claim 27, wherein the CBD, CBG and THC are collectively greater than 60% by weight of the cannabinoids present in the composition.

29. The composition of any one of the preceding claims, wherein the CBD, CBG and THC are present in a molar ratio between about 100:100:1 and about 1:1:

1.

30. The composition of claim 29, wherein the CBD, CBG and THC are present in a molar ratio is between about 100:50:1 and about 20:1:

1.

31. The composition of any one of the preceding claims, wherein the CBD and CBG are present in a molar ratio between about 100:1 and about 1:

1.

32. The composition of any one of the preceding claims, wherein the molar ratio of CBD and THC is between about 50:1 and about 1:

1.

33. The composition of any one of the preceding claims, further comprising at least one lipid excipient. sf-5716649776772000140 34. The composition of claim 33, wherein at least one lipid excipient is a winterized oil comprising long-chain mono-, di-, and triglycerides.

35. The composition of any one of the preceding claims, further comprising docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof.

36. The composition of any one of the preceding claims, wherein the composition is formulated for oral delivery.

37. A method for treating a neurodegenerative disease or condition, or a cancer in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a cannabinoid composition of any one of claims 1 to 36.

38. The method of claim 37, wherein the neurodegenerative disease or condition is associated with neuronal insult.

39. The method of claim 38, wherein the neuronal insult is characterized by intracellular aggregates of microtubule associated protein Tau.

40. The method of any one of claims 37 to 39, wherein the neurodegenerative disease or condition is Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia, epilepsy, concussion, stroke, or traumatic brain injury.

41. The method of any one of claims 37 to 40, wherein the method targets microtubule associated protein Tau.

42. A method for treating a tau-mediated disease or condition in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a cannabinoid composition of any one of claims 1 to 36.

43. The method of claim 42, wherein the disease or condition is characterized by intracellular aggregates of the microtubule associated protein Tau. sf-5716649776772000140 44. The method of 42 or 43, wherein the treatment at least partially reduces toxic gains of function, and / or at least partially restores or at least partially reduces normal Tau function in the subject.

45. The method of any one of claims 37 to 44, wherein the subject is a human. sf-5716649